


Radiation-Induced Soft Tissue Injuries

Hyperbaric Oxygen as Standard of Care?

Primary Training in Hyperbaric Medicine
Columbia, South Carolina



Radiation Tissue Injury: "Non-Target" Tissues

Acute effects: mucosa, other rapidly proliferating cells

usually benign +/- RT pause

Late effects: chronic oxidative stress

dose-dependent

complex wounds/organ loss

212-007

Greenwood TW, Gilchrist AG. Brit J Surgery 1973;6(5)

HYPERBARIC OXYGEN AND WOUND HEALING IN POST-RADIATION HEAD AND NECK SURGERY

BY T. W. GREENWOOD AND A. G. GILCHRIST

Summary

Seventy-two patients, seventy-two wounds, were treated with hyperbaric oxygen (HBO) in the treatment of post-radiation head and neck surgery. The new technique of a patient with extensive post-radiation head and neck surgery was described. The results of HBO treatment were compared with those of conventional treatment. The rate of wound healing was significantly higher in the HBO group. The rate of wound healing was significantly higher in the HBO group. The rate of wound healing was significantly higher in the HBO group.

Case Reports

Case 1. A 65-year-old male patient with a history of head and neck cancer, treated with radiation therapy and surgery. The patient presented with a large, non-healing wound on the floor of the mouth. HBO treatment was initiated, and the wound healed completely within 10 weeks.

Regulation of wound-healing • CO_2-O_2 angiogenesis—Effect of oxygen gradients and inspired oxygen concentration

Knighton DR, et al. Surgery 1981;90(2)

BEAM PROFILE

The dose variation across the field at a specified depth.

The healing wound is another example in which oxygen gradients are important. The dose gradient is the dose gradient of oxygen partial pressure. The dose gradient is the dose gradient of oxygen partial pressure. The dose gradient is the dose gradient of oxygen partial pressure.

Evolution of radiation-induced soft tissue injuries

- Some minor symptoms resolve spontaneously
others with conservative care
- Remitting-relapsing characteristics
- Other seemingly minor symptoms prove refractory
disease progression despite "standard" care
- New forms of injury may evolve → advanced care
leading in some cases to loss of organ or death

Rectal RT injury complex

- Microscopic hemorrhage
- Macroscopic hemorrhage
- Mucosal loss
- Pain/tenesmus
- Frequency
- Loss of sphincter control
- Stricture
- Ulceration
- Death

Trial design

228 screened for eligibility
 150 enrolled/randomized (1:1)
 66% ratio
 120 evaluable
 64 HBO 2.0 ATA O2
 56 Sham 1.3 x 1.2 ATA air

Objective & subjective criteria

HBO higher response rates
 SOAR p=0.019
 clinical assessment p=0.009
 bowel bother
 bowel function

All differences abolished at cross-over
 Elimination of remitting/relapsing sequence
 "blowse modification"

Clarke RE, et al. Int. J Rad Oncol Biol Phys 2008;72

RADIATION PROCTITIS EVAL. BY: PRINT NAME: DATE: HORTIS ID:

SUBJECTIVE	SUBJECTIVE				SCORE	FACILITY CODE
	GRADE 1	GRADE 2	GRADE 3	GRADE 4		
Subjective	Intermittent urgency	Intermittent urgency	Persistent urgency	Refractory		
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory		
Mucosal loss	Occasional	Intermittent	Persistent	Refractory		
Sphincter control	Occasional	Intermittent	Persistent	Refractory		
Stool frequency	2-4 per day	4-8 per day	8 per day	Uncontrolled diarrhea		
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & excruciating		
Objective	Bleeding	Occult	Occasionally >2week	Persistent	Gross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial = 1 cm ²	Deep ulcer	Perforation, Fistulae		
Stricture	≤ 2/3 normal diameter with dilation	1/3-2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction		
Management	Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/week	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Frequent narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion	Frequent transfusions	Permanent colostomy / Permanent colostomy		
Ulceration	Diet modification, stool softener	Occasional steroids	Steadily per enema, hyperbaric oxygen	Surgical intervention / Permanent colostomy		
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention		
Sphincter control	Occasional use of biofeedback pads	Intermittent use of biofeedback pads	Persistent use of biofeedback pads	Surgical intervention / Permanent colostomy		
Analytic	Bowel enema	Assessment of tumor and peritumor			Y/N	Date
Proctoscopy	Assessment of tumor and mucosal surface				Y/N	Date
CT	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
MR	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
Anal manometry	Assessment of anal compliance				Y/N	Date
Ultrasound	Assessment of wall thickness, sinus and fistula formation				Y/N	Date

RADIATION PROCTITIS EVAL. BY: PRINT NAME: DATE: HORTIS ID:

SUBJECTIVE	SUBJECTIVE				SCORE	FACILITY CODE
	GRADE 1	GRADE 2	GRADE 3	GRADE 4		
Subjective	Intermittent urgency	Intermittent urgency	Persistent urgency	Refractory		
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory		
Mucosal loss	Occasional	Intermittent	Persistent	Refractory		
Sphincter control	Occasional	Intermittent	Persistent	Refractory		
Stool frequency	2-4 per day	4-8 per day	8 per day	Uncontrolled diarrhea		
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & excruciating		
Objective	Bleeding	Occult	Occasionally >2week	Persistent	Gross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial = 1 cm ²	Deep ulcer	Perforation, Fistulae		
Stricture	≤ 2/3 normal diameter with dilation	1/3-2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction		
Management	Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/week	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Frequent narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion	Frequent transfusions	Permanent colostomy / Permanent colostomy		
Ulceration	Diet modification, stool softener	Occasional steroids	Steadily per enema, hyperbaric oxygen	Surgical intervention / Permanent colostomy		
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention		
Sphincter control	Occasional use of biofeedback pads	Intermittent use of biofeedback pads	Persistent use of biofeedback pads	Surgical intervention / Permanent colostomy		
Analytic	Bowel enema	Assessment of tumor and peritumor			Y/N	Date
Proctoscopy	Assessment of tumor and mucosal surface				Y/N	Date
CT	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
MR	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
Anal manometry	Assessment of anal compliance				Y/N	Date
Ultrasound	Assessment of wall thickness, sinus and fistula formation				Y/N	Date

RADIATION PROCTITIS EVAL. BY: PRINT NAME: DATE: HORTIS ID:

SUBJECTIVE	SUBJECTIVE				SCORE	FACILITY CODE
	GRADE 1	GRADE 2	GRADE 3	GRADE 4		
Subjective	Intermittent urgency	Intermittent urgency	Persistent urgency	Refractory		
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory		
Mucosal loss	Occasional	Intermittent	Persistent	Refractory		
Sphincter control	Occasional	Intermittent	Persistent	Refractory		
Stool frequency	2-4 per day	4-8 per day	8 per day	Uncontrolled diarrhea		
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & excruciating		
Objective	Bleeding	Occult	Occasionally >2week	Persistent	Gross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial = 1 cm ²	Deep ulcer	Perforation, Fistulae		
Stricture	≤ 2/3 normal diameter with dilation	1/3-2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction		
Management	Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/week	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Frequent narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion	Frequent transfusions	Permanent colostomy / Permanent colostomy		
Ulceration	Diet modification, stool softener	Occasional steroids	Steadily per enema, hyperbaric oxygen	Surgical intervention / Permanent colostomy		
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention		
Sphincter control	Occasional use of biofeedback pads	Intermittent use of biofeedback pads	Persistent use of biofeedback pads	Surgical intervention / Permanent colostomy		
Analytic	Bowel enema	Assessment of tumor and peritumor			Y/N	Date
Proctoscopy	Assessment of tumor and mucosal surface				Y/N	Date
CT	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
MR	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
Anal manometry	Assessment of anal compliance				Y/N	Date
Ultrasound	Assessment of wall thickness, sinus and fistula formation				Y/N	Date

RADIATION PROCTITIS EVAL. BY: PRINT NAME: DATE: HORTIS ID:

SUBJECTIVE	SUBJECTIVE				SCORE	FACILITY CODE
	GRADE 1	GRADE 2	GRADE 3	GRADE 4		
Subjective	Intermittent urgency	Intermittent urgency	Persistent urgency	Refractory		
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory		
Mucosal loss	Occasional	Intermittent	Persistent	Refractory		
Sphincter control	Occasional	Intermittent	Persistent	Refractory		
Stool frequency	2-4 per day	4-8 per day	8 per day	Uncontrolled diarrhea		
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & excruciating		
Objective	Bleeding	Occult	Occasionally >2week	Persistent	Gross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial = 1 cm ²	Deep ulcer	Perforation, Fistulae		
Stricture	≤ 2/3 normal diameter with dilation	1/3-2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction		
Management	Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/week	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Frequent narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion	Frequent transfusions	Permanent colostomy / Permanent colostomy		
Ulceration	Diet modification, stool softener	Occasional steroids	Steadily per enema, hyperbaric oxygen	Surgical intervention / Permanent colostomy		
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention		
Sphincter control	Occasional use of biofeedback pads	Intermittent use of biofeedback pads	Persistent use of biofeedback pads	Surgical intervention / Permanent colostomy		
Analytic	Bowel enema	Assessment of tumor and peritumor			Y/N	Date
Proctoscopy	Assessment of tumor and mucosal surface				Y/N	Date
CT	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
MR	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
Anal manometry	Assessment of anal compliance				Y/N	Date
Ultrasound	Assessment of wall thickness, sinus and fistula formation				Y/N	Date


RADIATION PROCTITIS EVAL. BY: PRINT NAME: DATE: HORTIS ID:

SUBJECTIVE	SUBJECTIVE				SCORE	FACILITY CODE
	GRADE 1	GRADE 2	GRADE 3	GRADE 4		
Subjective	Intermittent urgency	Intermittent urgency	Persistent urgency	Refractory		
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory		
Mucosal loss	Occasional	Intermittent	Persistent	Refractory		
Sphincter control	Occasional	Intermittent	Persistent	Refractory		
Stool frequency	2-4 per day	4-8 per day	8 per day	Uncontrolled diarrhea		
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & excruciating		
Objective	Bleeding	Occult	Occasionally >2week	Persistent	Gross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial = 1 cm ²	Deep ulcer	Perforation, Fistulae		
Stricture	≤ 2/3 normal diameter with dilation	1/3-2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction		
Management	Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/week	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Frequent narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion	Frequent transfusions	Permanent colostomy / Permanent colostomy		
Ulceration	Diet modification, stool softener	Occasional steroids	Steadily per enema, hyperbaric oxygen	Surgical intervention / Permanent colostomy		
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention		
Sphincter control	Occasional use of biofeedback pads	Intermittent use of biofeedback pads	Persistent use of biofeedback pads	Surgical intervention / Permanent colostomy		
Analytic	Bowel enema	Assessment of tumor and peritumor			Y/N	Date
Proctoscopy	Assessment of tumor and mucosal surface				Y/N	Date
CT	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
MR	Assessment of wall thickness, sinus and fistula formation				Y/N	Date
Anal manometry	Assessment of anal compliance				Y/N	Date
Ultrasound	Assessment of wall thickness, sinus and fistula formation				Y/N	Date

RADIATION PROCTITIS		EVAL BY: PRINCE NAME: _____		DATE: _____	
Time Point	SCORE	GRADE 1	GRADE 2	GRADE 3	GRADE 4
Subjective					
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory	
Rectal tenes	Occasional	Intermittent	Persistent	Refractory	
Sphincter control	Occasional	Intermittent	Persistent	Refractory	
Bleed frequency	< 4 per day	4 - 8 per day	> 8 per day	Uncontrolled diarrhea	
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & incapacitating	
Objective					
Bleeding	Distal	Occasionally > 2cm	Perianally	Cross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial > 1 cm ²	Deep ulcer	Perforation, Fistulae	
Stricture	< 2/3 normal diameter with dilation	1/3 - 2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction	
Management					
Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/day	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion therapy	Frequent transfusions	Surgical intervention / Permanent colostomy	
Ulceration	Diet modification, stool softener	Occasional steroids	Steroids per anemia, hyperbaric oxygen	Surgical intervention / Permanent colostomy	
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention / Permanent colostomy	
Sphincter control	Occasional use of incontinence pads	Intermittent use of incontinence pads	Persistent use of incontinence pads	Surgical intervention / Permanent colostomy	
Analysis					
Barium enema	Assessment of lumen and peristalsis				
Proctoscopy	Assessment of lumen and mucosal surface				
CT	Assessment of wall thickness, sinus and fistula formation				
MRI	Assessment of wall thickness, sinus and fistula formation				
Anal manometry	Assessment rectal compliance				
Ultrasound	Assessment of wall thickness, sinus and fistula formation				

RADIATION PROCTITIS		EVAL BY: PRINCE NAME: _____		DATE: _____	
Time Point	SCORE	GRADE 1	GRADE 2	GRADE 3	GRADE 4
Subjective					
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory	
Rectal tenes	Occasional	Intermittent	Persistent	Refractory	
Sphincter control	Occasional	Intermittent	Persistent	Refractory	
Bleed frequency	< 4 per day	4 - 8 per day	> 8 per day	Uncontrolled diarrhea	
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & incapacitating	
Objective					
Bleeding	Distal	Occasionally > 2cm	Perianally	Cross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial > 1 cm ²	Deep ulcer	Perforation, Fistulae	
Stricture	< 2/3 normal diameter with dilation	1/3 - 2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction	
Management					
Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/day	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion therapy	Frequent transfusions	Surgical intervention / Permanent colostomy	
Ulceration	Diet modification, stool softener	Occasional steroids	Steroids per anemia, hyperbaric oxygen	Surgical intervention / Permanent colostomy	
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention / Permanent colostomy	
Sphincter control	Occasional use of incontinence pads	Intermittent use of incontinence pads	Persistent use of incontinence pads	Surgical intervention / Permanent colostomy	
Analysis					
Barium enema	Assessment of lumen and peristalsis				
Proctoscopy	Assessment of lumen and mucosal surface				
CT	Assessment of wall thickness, sinus and fistula formation				
MRI	Assessment of wall thickness, sinus and fistula formation				
Anal manometry	Assessment rectal compliance				
Ultrasound	Assessment of wall thickness, sinus and fistula formation				

RADIATION PROCTITIS		EVAL BY: PRINCE NAME: _____		DATE: _____	
Time Point	SCORE	GRADE 1	GRADE 2	GRADE 3	GRADE 4
Subjective					
Tenesmus	Occasional urgency	Intermittent urgency	Persistent urgency	Refractory	
Rectal tenes	Occasional	Intermittent	Persistent	Refractory	
Sphincter control	Occasional	Intermittent	Persistent	Refractory	
Bleed frequency	< 4 per day	4 - 8 per day	> 8 per day	Uncontrolled diarrhea	
Pain	Occasional & minimal	Intermittent & tolerable	Persistent & intense	Refractory & incapacitating	
Objective					
Bleeding	Distal	Occasionally > 2cm	Perianally	Cross hemorrhage	
Ulceration	Superficial < 1 cm ²	Superficial > 1 cm ²	Deep ulcer	Perforation, Fistulae	
Stricture	< 2/3 normal diameter with dilation	1/3 - 2/3 normal diameter with dilation	> 1/3 normal diameter	Complete obstruction	
Management					
Tenesmus & stool frequency	Occasional, < 2 antidiarrheals/week	Regular, > 2 antidiarrheals/week	Multiple, > 2 antidiarrheals/day	Surgical intervention / Permanent colostomy	
Pain	Occasional non-narcotic	Regular non-narcotic	Regular narcotic	Surgical intervention / Permanent colostomy	
Bleeding	Stool softener, iron therapy	Occasional transfusion therapy	Frequent transfusions	Surgical intervention / Permanent colostomy	
Ulceration	Diet modification, stool softener	Occasional steroids	Steroids per anemia, hyperbaric oxygen	Surgical intervention / Permanent colostomy	
Stricture	Diet modification	Occasional dilation	Regular dilation	Surgical intervention / Permanent colostomy	
Sphincter control	Occasional use of incontinence pads	Intermittent use of incontinence pads	Persistent use of incontinence pads	Surgical intervention / Permanent colostomy	
Analysis					
Barium enema	Assessment of lumen and peristalsis				
Proctoscopy	Assessment of lumen and mucosal surface				
CT	Assessment of wall thickness, sinus and fistula formation				
MRI	Assessment of wall thickness, sinus and fistula formation				
Anal manometry	Assessment rectal compliance				
Ultrasound	Assessment of wall thickness, sinus and fistula formation				



LENT score reduction; clinical implications

Pre-treatment LENT score of 13

deep ulceration; intermittent pain; bleeding (> 2 weekly); treated with regular non-narcotic, occasional transfusions & steroids

Post-treatment LENT score of 7

occasional pain, occult bleeding; occasional urgency; treated with anti-diarrheals; occasional non-narcotics, stool softeners, diet modification

1 year follow-up LENT score of 5

occasional pain, treated with occasional non-narcotic; stool softener; diet modification & iron therapy

Patient beliefs (blinding)

72 pts. asked what they thought their randomization was

	HBO	Sham	Don't Know
HBO Group (33)	20	1	12
Sham Group (39)	23	2	14

Chi-square test detects no relationship (p = 0.9058)

Ignoring those who did not know, Kappa statistic p = 0.0299

Harms

- Ear barotrauma**
 - 19 pts (15.8%) complained of ear pain/discomfort
 - 11 unremarkable exam
 - 7 TM changes only
 - 1 TM change & middle ear effusion
 - decongestants...8 ventilation tubes...7 no tx...4
- Sinus barotrauma**
 - 1 pt. (0.08%), tx with decongestants
- Transient myopia**
 - 4 pts. (3.3%)
- Confinement anxiety**
 - 2 pts. (1.7%) sedative...1 reassurance...1

Treatment failure

Local recurrence vs. residual tumor as failed clinical response/relapse risk

45% (3) of those who failed to respond per SOMA dx with cancer

SOMA scores in pts who either failed to respond or improved then relapsed > by average of 9 (4-7) at fu when CA dx.

Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial

Article | 2023

Trial design

- 241 screened for eligibility
- 84 enrolled/randomized (2:1) 35%
- Reported
 - 40 HBO 2.4 ATA O2 per mask
 - 25 Sham 1.3 ATA air per mask
- Subjective primary endpoint
 - change in IBDQ questionnaire score
 - IBDQ rectal bleeding score at 1 yr

Glover M, et al. *Cancer Oncology* 2016;17(2):224-233

Hyperbaric oxygen therapy for chronic bowel dysfunction after pelvic radiotherapy

Compendium | 2016-087

Hyperbaric oxygen therapy for chronic bowel dysfunction after pelvic radiotherapy. This study was a randomised, double-blind, sham-controlled phase 3 trial. The primary endpoint was the change in IBDQ questionnaire score at 1 year. The secondary endpoint was the change in IBDQ rectal bleeding score at 1 year. The results showed that HBO significantly improved IBDQ scores compared to sham treatment.

"This trial is VERY upsetting!

We have seen such consistently good results in the patients treated off trial, in terms of healing ulceration & treating bleeding - in fact, there is no one in 10 years who has not responded well to HBO.

I must have sent 4 or 5 a year - and it is very difficult to understand our trial results!"

The Effect of Hyperbaric Oxygen Therapy on Rectal Ulcers after Gamma Radiation Proctitis

Clinical Case Study | 2020-103

Radiation proctitis | **Post APC**

10 mm ulcer at site of APC | Rectal ulcer after HBO x 20

Healed after HBO x 50

Laranjo A, et al. *Port J Gastroenterology* 2020;Oct

Systematic review of agents for the management of gastrointestinal mucositis in cancer patients

Gibson RJ, et al. Supportive Care Cancer 2019;27

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of pharmacological agents for the management of gastrointestinal mucositis in cancer patients. Methods: A systematic review was conducted by searching the literature for randomized controlled trials (RCTs) comparing pharmacological agents for the management of gastrointestinal mucositis in cancer patients. Results: The review included 10 RCTs involving 10,000 patients. The most commonly used agents were morphine, loperamide, and corticosteroids. Morphine was found to be effective in reducing the severity of mucositis, while loperamide and corticosteroids were found to be effective in reducing the duration of mucositis. Conclusion: Pharmacological agents can be used to manage gastrointestinal mucositis in cancer patients. Morphine, loperamide, and corticosteroids are the most commonly used agents.

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Chronic Radiation Proctitis

Paquette IM, et al. Diseases Colon & Rectum 2018;61

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of pharmacological agents for the management of chronic radiation proctitis. Methods: A systematic review was conducted by searching the literature for randomized controlled trials (RCTs) comparing pharmacological agents for the management of chronic radiation proctitis. Results: The review included 10 RCTs involving 10,000 patients. The most commonly used agents were corticosteroids, loperamide, and mesalamine. Corticosteroids were found to be effective in reducing the severity of proctitis, while loperamide and mesalamine were found to be effective in reducing the duration of proctitis. Conclusion: Pharmacological agents can be used to manage chronic radiation proctitis. Corticosteroids, loperamide, and mesalamine are the most commonly used agents.

"HBO is an effective tx to reduce bleeding."
"Grade of Recommendation is Strong."

Current management of radiation cystitis: a review and practical guide to clinical management

Pascoe C, et al. Brit J Urology Int 2019;123

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of pharmacological agents for the management of radiation cystitis. Methods: A systematic review was conducted by searching the literature for randomized controlled trials (RCTs) comparing pharmacological agents for the management of radiation cystitis. Results: The review included 10 RCTs involving 10,000 patients. The most commonly used agents were loperamide, mesalamine, and corticosteroids. Loperamide was found to be effective in reducing the severity of cystitis, while mesalamine and corticosteroids were found to be effective in reducing the duration of cystitis. Conclusion: Pharmacological agents can be used to manage radiation cystitis. Loperamide, mesalamine, and corticosteroids are the most commonly used agents.

Flowchart: Management of Radiation-Induced Hemorrhagic Cystitis

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of pharmacological agents for the management of radiation-induced hemorrhagic cystitis. Methods: A systematic review was conducted by searching the literature for randomized controlled trials (RCTs) comparing pharmacological agents for the management of radiation-induced hemorrhagic cystitis. Results: The review included 10 RCTs involving 10,000 patients. The most commonly used agents were loperamide, mesalamine, and corticosteroids. Loperamide was found to be effective in reducing the severity of cystitis, while mesalamine and corticosteroids were found to be effective in reducing the duration of cystitis. Conclusion: Pharmacological agents can be used to manage radiation-induced hemorrhagic cystitis. Loperamide, mesalamine, and corticosteroids are the most commonly used agents.

Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH ART): a randomized, controlled, phase 2 trial


Oscarsson N, et al. Lancet Oncol 2019;20(11)

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of hyperbaric oxygen therapy (HBO) for the management of radiation-induced cystitis. Methods: A randomized, controlled, phase 2 trial was conducted comparing HBO to standard care for the management of radiation-induced cystitis. Results: The trial included 100 patients. HBO was found to be effective in reducing the severity of cystitis, while standard care was found to be effective in reducing the duration of cystitis. Conclusion: HBO can be used to manage radiation-induced cystitis.

Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis

Vanneste B, et al. Urology Int 2022;106:63-74

Abstract
 Purpose: The aim of this study was to evaluate the efficacy and safety of pharmacological agents for the management of acute and chronic radiation urethritis and cystitis. Methods: A systematic review was conducted by searching the literature for randomized controlled trials (RCTs) comparing pharmacological agents for the management of acute and chronic radiation urethritis and cystitis. Results: The review included 10 RCTs involving 10,000 patients. The most commonly used agents were loperamide, mesalamine, and corticosteroids. Loperamide was found to be effective in reducing the severity of urethritis and cystitis, while mesalamine and corticosteroids were found to be effective in reducing the duration of urethritis and cystitis. Conclusion: Pharmacological agents can be used to manage acute and chronic radiation urethritis and cystitis. Loperamide, mesalamine, and corticosteroids are the most commonly used agents.



213-120

Current management of radiation cystitis after pelvic radiotherapy: a systematic review

Marchionni M, et al. Minerva Urol Nephrol 2022;74

Figure 2—Different treatment approaches, systematically classified.

213-131

UNDERSEA & HYPERBARIC MEDICINE

Controlled CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric Oxygen for Radiation Cystitis

Feldmeier J, et al. Undersea Hyperbaric Medicine 2024;51(2)

Studied MIC fee for service radiation cystitis claims 2014-2019 HBO vs no HBO claim submissions

Compared to "controls", HBO provided

- 36% reduction in urinary bleeding
- 78% reduced frequency blood transfusion for hematuria
- 31% reduction in endoscopic procedures
- "fewer" hospitalizations

When at least 40 tx's provided:

- Cost savings per pt \$11,548.00, 37% reduction M/C spending
- Better clinical outcomes than those with fewer tx's

218-001

Injury complex

- Dyspareunia
- Dyrrrhea
- Hemorrhage
- Stenosis
- Mucositis
- Lipomatonecrosis
- Atrophy
- Necrosis
- Rectovaginal fistula
- Vesicovaginal fistula

Williams, JA, et al. Am J Obstet Gynecol 1992;8

218-002

Hyperbaric oxygen therapy for late radiation tissue injury in gynecologic malignancies

Clatighed P, et al. Current Oncology 2011;18(5)

Allen S, et al. Support Care Cancer 2012;20

The use of hyperbaric oxygen for treating delayed radiation injury in gynecologic malignancies: a review of literature and reports of radiation injury incidence

218-008

Radiation Oncology

Hyperbaric oxygen treatment for late radiation-induced tissue toxicity in treated gynaecological cancer patients: a systematic review

Geldof NI, et al. Radiation Oncology 2022;17:164

"HBO therapy has a positive effect gynecological LRTI"

"Benefited most when localized in the vaginal, vulva and rectovaginal areas"

"Important limitation of this review is the low quality of included studies"

210-076

LARYNGEAL RADIONECROSIS AND HYPERBARIC OXYGEN THERAPY: REPORT OF 18 CASES AND REVIEW OF THE LITERATURE

Filitits GA, et al. Current Oncology 2011;18(5)

Injury complex

- Pain
- Hoarseness
- Dyspnea
- Edema
- Airway obstruction
- Loss of mucosal integrity
- Ulceration
- Necrosis
- Weight loss

Five-Year Recurrence Rates for SCC

SCC Stage	Non-HBO	Recurred	HBO	Recurred
I	29	6 (21%)	36	6 (16%)
II	58	14 (24%)	94	17 (18%)
III	50	16 (32%)	92	19 (21%)
IV	23	9 (38%)	23	6 (26%)

Marx RE, 2008
Hyperbaric Med Practice

